tbuckley/cabot-search huggingface dataset:
Clinical activity of transdermal estradiol in patients with hormone and chemotherapy refractory prostate cancer
Authors: S. Chhabra, S. Doyle-Lindrud, C. Jeyamohan, D. Metzger, M. B. Todd, R. S. DiPaola, S. Goodin, M. N. Stein
Journal: Journal of Clinical Oncology (2007)

15619 Background: Oral estrogens are an effective treatment for metastatic hormone refractory prostate cancer but are not used because of an increased cardiovascular risk, particularly thromboembolism. Use of alternative formulations that bypass first pass metabolism may be safer and more effective. Therefore, we evaluated the anticancer safety and efficacy of transdermal estradiol (TDE) in patients with hormone refractory prostate cancer. Methods: Patients with metastatic prostate cancer who had progressed on hormonal therapy and at least one chemotherapy regimen that included docetaxel (median of 2 prior regimens, range 1–5) were treated with four TDE 0.1 mg/24 hour patches which were changed every 7 days until disease progression or unacceptable toxicity occurred. Serum prostate- specific antigen (PSA) levels were followed at regular intervals. End-points included PSA response, measurable disease response, time-to- progression (TTP), toxicity and quality of life. Results: In this ongoing trial, two patients out of eleven had a PSA response (confirmed PSA decline by = 50%). In five of the nine patients who did not have a ≥ 50% biochemical response to therapy, the PSA level declined between 2.1% and 25.4%, with a median of 19.9%. Two of the eleven patients have continued on study and are on week 9 and week 14, respectively. For the remaining nine patients who are now of study, the TTP ranged from 4 to 19 weeks, with a median duration of 8 weeks. Treatment toxicity included grade 1 nausea, breast enlargement/ tenderness and/or leg edema in six patients. No thromboembolic or cardiovascular events occurred. Conclusions: Early analysis of this ongoing study reveals modest antitumor activity of TDE with minimal toxicity in heavily pretreated patients with hormone refractory prostate cancer. No significant financial relationships to disclose.
PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 REGULATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS UNDER PROTEASE INHIBITORS
Authors: Franck Boccara, Mathilde Ghislain, Laurence Meyer, Cecile Goujard, Cedric Le May, Corinne Vigouroux, Jean Philippe Bastard, Soraya Fellahi, Jacqueline Capeau, Ariel Cohen, Bertrand Cariou
Journal: Journal of the American College of Cardiology (2017)
Non-myeloablative peripheral blood stem cell transplant in a patient with platelet (HPA) mismatch and pre-existing anti-donor platelet alloantibodies
Authors: M. R. Greene, Z. Szczepiorkowski, K. R. Meehan
Journal: Journal of Clinical Oncology (2007)

17541 Background: Platelets display a series of polymorphic epitopes which are known as the human platelet alloantigen (HPA) system. Alloantibodies directed against these HPA epitopes cause platelet destruction resulting in thrombocytopenia and refractoriness to platelet transfusions. We describe the rare and unique clinical course of a 61 year old patient with relapsed Non-Hodgkin’s lymphoma (NHL) who received an HLA matched, sibling, non-myeloablative, peripheral blood stem cell transplant (PBSCT) who had alloantibodies directed against a mismatched donor HPA antigen prior to transplant. Methods: The patient received a conditioning regimen of fludarabine (25 mg/m 2 QD x4) and cyclophosphamide (1 g/m 2 QD x2) followed by stem cell infusion. Graft versus host disease prophylaxis consisted of cyclosporine (1.5 mg/kg BID) and methotrexate (10 mg/m2 QD x 3) per routine protocol. Additionally, to protect donor platelets against the recipient’s alloantibody, the patient received 500 mg/kg gamma globulin (IVIG) on day -2 and +5. Results: The anticipated period of pancytopenia developed, with neutrophil and platelet engraftment occurring on day 19 and 29, respectively. The patient required only two platelet transfusions and did not experience bleeding. The patient remains in remission four years post transplant. Her platelet count is normal off immunosuppression. Conclusions: We have demonstrated that non-myeloablative transplant is possible in an HPA mismatched graft with detectable recipient anti-donor HPA alloantibodies using IVIG prophalaxis, in addition to routine immunosuppression. This has not been previously reported. We additionally provide a timeline showing time to platelet recovery and anti-platelet antibody kinetics that will be helpful in directing the care of future patients. No significant financial relationships to disclose.
LEFT VENTRICULAR SYSTOLIC RECOVERY AFTER ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: EFFECT OF GUIDELINE-BASED THERAPY
Authors: Rachid Abou, Melissa Leung, Georgette Hoogslag, Martin Schalij, Nina Ajmone Marsan, Jeroen Bax, Victoria Delgado
Journal: Journal of the American College of Cardiology (2017)
Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657)
Authors: A. DeMichele, L. Dunn, P. Gimotty, C. Livasy, C. Perou, L. Carey, L. Esserman
Journal: Journal of Clinical Oncology (2009)

11091 Background: Loss of expression of the cyclin-dependent kinase (cdk) inhibitor p27 has been associated with decreased survival among patients receiving adjuvant chemotherapy. The I-SPY Trial is a multicenter study of locally advanced breast cancer in which pretreatment tumor biopsies were obtained prior to the administration of anthracycline and taxane-based neoadjuvant therapy, and serial MRIs were performed to assess response to treatment. The aim of this study was to determine if loss of tumor p27 expression was associated with response to cytotoxic therapy. Methods: Eligible patients had biopsy-confirmed primary breast cancer measuring at least 3 cm. Immunohistochemistry for p27 was performed centrally on pretreatment core samples using rabbit anti-p27 (Upstate Cell Signaling #06–445). Nuclear p27 was classified as absent (no staining), low (1–50% staining) or normal (&gt;50% staining). Following completion of chemotherapy, post-surgical excision/mastectomy cases were reviewed centrally to determine response to therapy including residual cancer burden (RCB) and pathologic complete response (pCR) rate. Exact Chi2 was used to compare proportions. Results: Pretreatment samples from 164 of 237 enrolled patients demonstrated that p27 expression was absent in 55 (33%), low in 96 (58%) and normal in 14 (8%). P27 loss was not associated with patient age. Compared to normal p27 expression, absent p27 was significantly associated with ER negativity (48% vs. 14%; p=0.03), PR negativity (59% vs. 21%; p=0.03), Her2 overexpression (28% vs. 14%; p=0.017) and basal molecular subtype (29% vs. 13%). The proportion of patients with p27 loss (absent or low) was higher for those with high Ki-67 expression compared to low/mod expression (98% compare to 88%) and lower for grade 1 (72% vs 92%) compared to grade 2/3 tumors (p=0.071 and p=0.090, respectively). Low or absent p27 was not associated with response to therapy as measured by pCR, RCB or change in tumor diameter by MRI. Conclusions: p27 loss in this neoadjuvant patient population was associated with aggressive tumor features, but not predictive of response to cytotoxic therapy. These findings suggest that the poor prognosis associated with loss of p27 is not due to relative chemotherapy resistance. No significant financial relationships to disclose.
Impact of direct physician-to-physician contact on accelerating oncology clinical trial accrual
Authors: J. R. Eckardt, N. Ku, A. DeMaggio, M. Reese, M. Levonyak, V. Jain
Journal: Journal of Clinical Oncology (2009)

6613 Background: The development of more effective oncology agents is critically dependent on the completion of clinical trials; currently, &gt;4000 oncology trials listed in www.clinicaltrials.gov are accruing pts in the US. Unfortunately, only 3–5% of new cancer pts participate in clinical trials and most trials do not meet their projected accrual timelines. Barriers to pt accrual include physician awareness &amp; attitudes, access to protocols, administrative burdens to conduct clinical trials, cost to physicians and pts, and pt concerns about participation in research trials. To overcome at least some of these barriers, we investigated a strategy to improve clinical trial accrual that optimizes trial placement and awareness through a direct physician to physician intervention. Methods: For each site, a customized enrollment plan is established after initial assessment of interest and accrual potential. Implementation of the enrollment plan includes clinical communications and medical support delivered through direct physician to physician interactions. From Feb 2008 to December 2008, we implemented this strategy to increase accrual to 5 oncology trials (2 placebo controlled randomized trials and 3 phase II trials in breast cancer, non-Hodgkin's lymphoma and soft tissue sarcoma). Results: The implementation of direct physician to physician intervention resulted in a measurable improvement of between 50 - 300% in the monthly accrual to each of these 5 trials. Despite being significantly behind projections, 2 of the trials have now completed accrual on schedule. In the ongoing phase III study, accrual has improved from an average of 3.8 pts/mo to 13.5 pts/mo. Conclusions: The use of our current model of optimizing trial placement and awareness through a direct physician to physician intervention has been successful in significantly accelerating clinical trial accrual in 5/5 trials initiated to date. [Table: see text] [Table: see text]
DOES TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION (TAPSE) ADEQUATELY DESCRIBE RIGHT VENTRICULAR FUNCTION IN HYPOPLASTIC LEFT HEART SYNDROME?
Authors: Ololade Akintoye, Curtis Travers, William Border, Christopher J. Petit, Erik Michelfelder, Ritu Sachdeva
Journal: Journal of the American College of Cardiology (2017)
NON-INVASIVE FUNCTIONAL AND ANATOMICAL DIAGNOSTIC TESTING FOR PATIENTS WITH LOW-RISK ACUTE CORONARY SYNDROMES: A NETWORK META-ANALYSIS OF DIAGNOSTIC RANDOMIZED CONTROLLED TRIALS
Authors: Georgios Siontis, Dimitris Mavridis, Konstantinos Siontis, Bernadette Coles, Peter Jüni, Georgia Salanti, Stephan Windecker
Journal: Journal of the American College of Cardiology (2017)
Profile study: Genetic prostate cancer risk stratification for targeted screening.
Authors: Elena Castro, Elizabeth Bancroft, Natalie Taylor, Tokhir Dadaev, Elizabeth Page, Diana Keating, Nigel Borley, Nandita DeSouza, Ed Saunders, Andrew Lee, David Neal, Antonis C. Antoniou, Zsofia Kote-Jarai, Ros A. Eeles
Journal: Journal of Clinical Oncology (2013)

5054 Background: Prostate cancer (PC) screening is controversial and better approaches are needed, including a better assessment of individualized PC risk. Several studies have identified a number of common single nucleotide polymorphisms (SNPs) that confer a cumulative risk of PC. We have explored the potential role of genetic markers in identifying men who should be selectively targeted for screening in a population with increased risk of PC due to family history (FH) of the disease. Methods: PROFILE has been developed as a pilot study. The primary aim is to determine the feasibility of targeted PC screening using prostatic biopsy (PB) and its association with specific genetic profiles in men with FH. Secondary aims are to evaluate the role of PSA and Diffusion Weighted MRI (DW-MRI) as screening tools in this population. From December 2010 men aged 40-69 with FH of PC were invited into the study until 100 men were enrolled. Blood samples were provided for PSA and DNA extraction. The cumulative SNP risk scores for each patient were calculated by summing 59 risk alleles for each locus using the weighted effect as estimated in previous studies (log-additive model). DW-MRI was performed in 50 patients. All participants were asked to undergo a 10 core PB regardless of baseline PSA. Those who declined PB have been excluded from this analysis. Data on side effects and cancer worry were also collected. Results: 35% of invited men entered the study. Median age was 53 yrs (40-69) and median PSA was 1.15. Ninety men accepted to undergo a PB as primary PC screening. Twenty-two tumours were found and 45% of them were clinically significant [Median age 64yrs (47-69), median PSA 5.4 (0.91-9.3)]. The predictive performance of DW-MRI, PSA, genetic model and genetic model plus PSA measured by AUC were: 0.85, 0.73, 0.57 and 0.74, respectively. The genetic model performed better in men with PSA&lt;3(AUC 0.63). No severe side effect or adverse psychosocial variables were noted. Conclusions: Our results indicate that PB is acceptable as a means of PC screening in men with FH of PC. Overall, DW-MRI and PSA were more predictive of PC than the genetic risk score. As more SNPs are found, a larger study is warranted to evaluate their role in the PC screening algorithm.
Measuring Postconcussive Activity Levels of Patients
Authors: Ka Yiu Lee, Michael Huen Sum Lam, Yazhuo Deng
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
ASSESSMENT OF THROMBOGENICITY AND ANTITHROMBOTIC DRUG RESPONSE AT THE BEDSIDE IN PATIENTS PRESENTING WITH ISCHEMIC STROKE, TIA OR INTRACRANIAL HEMORRHAGE
Authors: Paul A. Gurbel, Kevin Bliden, Trish Brannan, Carlos Lopez-Espina, Christopher McLeod, Eli Cohen, Gabriel Raviv, Adina Muresan, Udaya Tantry, John Cochran
Journal: Journal of the American College of Cardiology (2017)
Hematopoietic Stem Cell Therapy In Eight Patients with Metachromatic Leukodystrophy – Relevance of Post-Transplant Medication.
Authors: Judith Böhringer, Birgit Kustermann-Kuhn, Friederike Gieseke, Annika Erbacher, Michaela Döring, Christiane Kehrer, Peter Lang, Ingeborg Krägeloh-Mann, Rupert Handgretinger, Ingo Müller
Journal: Blood (2010)
Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.
Authors: Sanjay Goel, Teresa Moran, Cinthya Coronado, Santiago Viteri Ramirez, Imran Chaudhary, Mohammad Haroon Ghalib, Umang Swami, Yijuan Hou, Enric Carcereny, Jose Alcantara, Jorge Luis Iglesias Dios, Bernardo De Miguel, Cristina Buges, Rafael Rosell
Journal: Journal of Clinical Oncology (2012)

3093 Background: E is a new marine compound that has shown synergism with T in vitro even in T-resistant non-small-cell lung cancer (NSCLC) cell lines. Based on these findings, a phase I clinical trial was undertaken to identify the maximum tolerated dose (MTD) and recommended dose (RD) of E (3-h iv, days 1, 8 and 15) followed by T (once daily) in 3-week cycles. Secondary objectives were evaluation of safety and feasibility, PK and preliminary efficacy results. Methods: Patients (pts) with advanced solid tumors with no standard therapeutic option were recruited. Cohorts of 3-6 pts were included at each dose level (DL), with escalating doses of E in increments of 25-50% according to toxicities, and 2 different T doses (100 and 150 mg/day). Results: Thirty pts (median age, 57 years; 19 females) were evaluable. Main tumor types included NSCLC, colorectal, melanoma, and ovarian cancer. Six DLs were assessed. Starting DL was E 0.33 mg + T 100mg. One dose-limiting toxicity (DLT) out of 6 pts (grade 3 bilirubin increase) was observed at DL3 (E 0.75 mg + T 150 mg). Another DLT (dose omissions due to ALT increase) was found at DL6 (E 2.25 mg + T 100 mg). Frequent toxicities were diarrhea (53%), nausea (23%), vomiting (33%), rash (47%), pruritus (43%), dry skin (27%) and acneiform dermatitis (17%). Grade 3/4 toxicities included diarrhea (2 pts), rash (2 pts) and pruritus (1 pts). Main biochemical abnormalities were ALT (grade 3/4 in 4 pts) and total bilirubin increase (grade 3 in 2 pts). No severe hematological abnormalities were observed. Most toxicities were related to T; therefore, T dose was reduced to 100 mg/day. No PK interaction between E and T was observed. No objective responses were reported. Six pts attained stable disease &gt;3 months (3 NSCLC; 1 ovarian cancer, 1 colorectal cancer, 1 invasive thymoma). Conclusions: E + T was a manageable combination; however, the difficulty of combining E with the standard dose of T (150mg) and the lack of activity made this combination unattractive for further development in the current schedule. Possibly, other schedules may demonstrate more efficacy.
ALIROCUMAB TITRATION STRATEGY ALLOWS INDIVIDUALIZED LDL-C REDUCTION IN A REAL WORLD SETTING: RESULTS FROM ODYSSEY OLE (LONG TERM COHORT)
Authors: Robert Dufour, G. Kees Hovingh, John Guyton, Gisle Langslet, Marie Baccara-Dinet, Chantal Din-Bell, Garen Manvelian, Michel Farnier
Journal: Journal of the American College of Cardiology (2017)
Correlation between spiral CT and PET in patients with advanced GIST refractory to high-dose imatinib: A GEIS study
Authors: D. Fuster, A. Sierra, J. R. Ayuso, A. Poveda, R. Cubedo, A. Casado, J. Martínez-Trufero, A. López-Pousa, X. Garcia Del Muro, J. Maurel
Journal: Journal of Clinical Oncology (2009)

10553 Background: Small changes in tumor size or density on computed tomography (CT) are sensitive and specific methods to assess response of GISTs and correlates well with positron emission tomography with 18F-Fluorodeoxyglucose (FDG-PET) in untreated GIST patients (pts). Despite of it, there is inconsistent prospective data in imatinib (IM) refractory disease. Methods: This multicenter phase I-II study prospectively evaluated 26 pts with metastatic high-dose IM refractory GISTs treated with doxorubicin 15 - 20 mg/m2/weekly per 4 cycles, followed by IM maintanance (400mg p.o.qd). CT and FDG-PET were performed at baseline and after 2 months of therapy. Response rate was assessed by RECIST criteria by Principal Investigator (PI). CT and FDG-PET (EORTC criteria) were reviewed by two experts in abdominal CT (AR) and one expert on Nuclear Medicine in one Institution. Results: Tumor density measurements were not assessed on CT because some studies were not available in DICOM format and different tube currents were used. There were significant lower number of lesions identified by PI (n=73; median 2, range 1–6) than AR (n=122; median 5, range 1–10). Twenty-eight out of 122 lesions identified by CT did not demonstrate significant uptake in FDG-PET at baseline (upon 800mg/day of IM treatment) on FDG-PET. Mean baseline tumor size on CT was 5.9cm (ranging from 0.9 to 28cm), and mean baseline SUVmax on FDG-PET was 7.2 (ranging from 1.9 to 26.4). Nine patients responded on FDG-PET compared with 2 pts and 5 pts with RECIST or modified RECIST criteria (decrease in tumor size more than 10%), respectively. The sensitivity for RECIST or modified RECIST in identifying PET responders was 22% and 55%, showing a 100% of specificity by both methods. Good responders on FDG-PET at 2 months had significantly longer progression free survival (264 days) than non-responders (64 days) (P=0.01). Conclusions: FDG-PET is sensitive and specific to assess response of GISTs pts refractory to high-dose IM. If the prognostic value of FDG-PET can be confirmed should be employed in future studies of pts with refractory GIST. No significant financial relationships to disclose.
Diagnostic Challenges in Patients With Tumors
Authors: Ashwani Rajput, Peter A. Loud, John F. Gibbs, William G. Kraybill
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.02.092 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 14512403 Diagnostic Challenges in Patients With Tumors CASE 1. GOSSYPIBOMA (FOREIGN BODY) MANIFESTING 30 YEARS AFTER LAPAROTOMY Ashwani RajputxAshwani RajputSearch for articles by this author , Peter A. LoudxPeter A. LoudSearch for articles by this author , John F. GibbsxJohn F. GibbsSearch for articles by this author , William G. KraybillxWilliam G. KraybillSearch for articles by this author Show More Roswell Park Cancer Institute and the State University of New York at Buffalo, Buffalo, NY https://doi.org/10.1200/JCO.2003.02.092 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Exome analysis of the evolutionary path of hepatocellular adenoma-carcinoma transition, vascular invasion and brain dissemination
Authors: Sílvia Vilarinho, E. Zeynep Erson-Omay, Kisha Mitchell-Richards, Charles Cha, Carol Nelson-Williams, Akdes Serin Harmancı, Katsuhito Yasuno, Murat Günel, Tamar H. Taddei
Journal: Journal of Hepatology (2017)
The Assessment of Physical Fitness by Correlation of Vital Capacity and Certain Measurements of the Body.
Journal: JAMA (1921)

p\att 20.Normal weight of body in pounds and decimals of pounds, and in pounds and ounces, calculated from circumference of chest given in inches and eighths of inches 93 21.Normal circumference of chest in inches and decimals of inches, and in inches and eighths of inches, calculated from length of trunk given in inches and eighths of inches 97 22. Normal vital capacity in cubic centimetres calculated from tt»ez^A/ of body given in pounds 100 23.Normal vital capacity in cubic centimetres calculated from length of tru7ik given in inches and eighths of inches 104 24.Normal vital capacity in cubic centimetres calculated from circumference of chest given in inches and eighths of inches